Regulation of the Hippo pathway and implications for anticancer drug development

Trends in Pharmacological Sciences

Volumn 34, Issue 10, 2013, Pages 581-589

  Park, Hyun Woo ^a   Guan, Kun Liang ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

GPCR cancer; Hippo pathway; YAP phosphorylation

Indexed keywords

ADRENALIN; ALPHA CATENIN; BETA CATENIN; COLEUSIN FACTOR; CYCLIC AMP; DOBUTAMINE; EPIDERMAL GROWTH FACTOR; FORSKOLIN DERIVATIVE; FSK 88; G PROTEIN COUPLED RECEPTOR; IBUDILAST; IDRONOXIL; PDZ PROTEIN; PROTEIN 14 3 3; PROTEIN SERINE THREONINE KINASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; ROLIPRAM; SMAD PROTEIN; SOMATOMEDIN; SPHINGOSINE KINASE 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; CELL POLARITY; CELL SURVIVAL; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME REPRESSION; GENE MUTATION; GENE TARGETING; HIPPO PATHWAY; HUMAN; INTRACELLULAR SIGNALING; LOW DRUG DOSE; MECHANOTRANSDUCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

EID: 84885182528     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2013.08.006     Document Type: Review

References (108)

1. D. Pan The hippo signaling pathway in development and cancer Dev. Cell 19 2010 491 505
2. F.X. Yu, and K.L. Guan The Hippo pathway: regulators and regulations Genes Dev. 27 2013 355 371
3. K.F. Harvey The Hippo pathway and human cancer Nat. Rev. Cancer 13 2013 246 257
4. K. Harvey, and N. Tapon The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network Nat. Rev. Cancer 7 2007 182 191
5. S. Wu hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts Cell 114 2003 445 456
6. B.A. Callus Association of mammalian sterile twenty kinases, Mst1 and Mst2, with hSalvador via C-terminal coiled-coil domains, leads to its stabilization and phosphorylation FEBS J. 273 2006 4264 4276
7. M. Praskova MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell proliferation Curr. Biol. 18 2008 311 321
8. B. Zhao The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal Nat. Cell Biol. 13 2011 877 883
9. J.M. Lamar The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain Proc. Natl. Acad. Sci. U.S.A. 109 2012 E2441 E2450
10. B. Zhao TEAD mediates YAP-dependent gene induction and growth control Genes Dev. 22 2008 1962 1971
11. J.S. Mo Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs) Genes Dev. 26 2012 2138 2143
12. F.X. Yu Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling Cell 150 2012 780 791
13. E. Miller Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP Chem. Biol. 19 2012 955 962
14. R. Lappano, and M. Maggiolini G protein-coupled receptors: novel targets for drug discovery in cancer Nat. Rev. Drug Discov. 10 2011 47 60
15. M. O'Hayre The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer Nat. Rev. Cancer 13 2013 412 424
16. A.V. Smrcka Molecular targeting of Gα and Gβγ subunits: a potential approach for cancer therapeutics Trends Pharmacol. Sci. 34 2013 290 298
17. M. Kim cAMP/PKA signalling reinforces the LATS-YAP pathway to fully suppress YAP in response to actin cytoskeletal changes EMBO J. 32 2013 1543 1555
18. F.X. Yu Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation Genes Dev. 27 2013 1223 1232
19. Y. Bao A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription J. Biochem. 150 2011 199 208
20. Z. Kan Diverse somatic mutation patterns and pathway alterations in human cancers Nature 466 2010 869 873
21. X. Varelas, and J.L. Wrana Coordinating developmental signaling: novel roles for the Hippo pathway Trends Cell Biol. 22 2012 88 96
22. B. Zhao Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control Genes Dev. 21 2007 2747 2761
23. R. Fan Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1 Proc. Natl. Acad. Sci. U.S.A. 110 2013 2569 2574
24. K. Strassburger Insulin/IGF signaling drives cell proliferation in part via Yorkie/YAP Dev. Biol. 367 2012 187 196
25. M. Imajo A molecular mechanism that links Hippo signalling to the inhibition of Wnt/β-catenin signalling EMBO J. 31 2012 1109 1122
26. X. Varelas The Hippo pathway regulates Wnt/β-catenin signaling Dev. Cell 18 2010 579 591
27. E.R. Barry Restriction of intestinal stem cell expansion and the regenerative response by YAP Nature 493 2013 106 110
28. L. Azzolin Role of TAZ as mediator of Wnt signaling Cell 151 2012 1443 1456
29. B. Zhao Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis Genes Dev. 26 2012 54 68
30. G. Halder Transduction of mechanical and cytoskeletal cues by YAP and TAZ Nat. Rev. Mol. Cell Biol. 13 2012 591 600
31. A. Genevet, and N. Tapon The Hippo pathway and apico-basal cell polarity Biochem. J. 436 2011 213 224
32. K. Wada Hippo pathway regulation by cell morphology and stress fibers Development 138 2011 3907 3914
33. B. Zhao Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein Genes Dev. 25 2011 51 63
34. X. Varelas The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-β-SMAD pathway Dev. Cell 19 2010 831 844
35. K. Schlegelmilch Yap1 acts downstream of α-catenin to control epidermal proliferation Cell 144 2011 782 795
36. M.C. Schroeder, and G. Halder Regulation of the Hippo pathway by cell architecture and mechanical signals Semin. Cell Dev. Biol. 23 2012 803 811
37. N.G. Kim E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components Proc. Natl. Acad. Sci. U.S.A. 108 2011 11930 11935
38. A. Reginensi Yap- and Cdc42-dependent nephrogenesis and morphogenesis during mouse kidney development PLoS Genet. 9 2013 e1003380
39. D.T. Butcher A tense situation: forcing tumour progression Nat. Rev. Cancer 9 2009 108 122
40. M.J. Paszek Tensional homeostasis and the malignant phenotype Cancer Cell 8 2005 241 254
41. F. Calvo Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts Nat. Cell Biol. 15 2013 637 646
42. S. Dupont Role of YAP/TAZ in mechanotransduction Nature 474 2011 179 183
43. B. Zhao A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(β-TRCP) Genes Dev. 24 2010 72 85
44. Y. Hao Tumor suppressor LATS1 is a negative regulator of oncogene YAP J. Biol. Chem. 283 2008 5496 5509
45. H. Oh, and K.D. Irvine In vivo regulation of Yorkie phosphorylation and localization Development 135 2008 1081 1088
46. Q.Y. Lei TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway Mol. Cell. Biol. 28 2008 2426 2436
47. C.Y. Liu The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCFβ-TrCP E3 ligase J. Biol. Chem. 285 2010 37159 37169
48. M. Sudol, and K.F. Harvey Modularity in the Hippo signaling pathway Trends Biochem. Sci. 35 2010 627 633
49. M. Sudol Structures of YAP protein domains reveal promising targets for development of new cancer drugs Semin. Cell Dev. Biol. 23 2012 827 833
50. W. Wang Angiomotin-like proteins associate with and negatively regulate YAP1 J. Biol. Chem. 286 2011 4364 4370
51. S.W. Chan Hippo pathway-independent restriction of TAZ and YAP by angiomotin J. Biol. Chem. 286 2011 7018 7026
52. W. Wang PTPN14 is required for the density-dependent control of YAP1 Genes Dev. 26 2012 1959 1971
53. X. Liu PTPN14 interacts with and negatively regulates the oncogenic function of YAP Oncogene 32 2013 1266 1273
54. H.I. Chen, and M. Sudol The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules Proc. Natl. Acad. Sci. U.S.A. 92 1995 7819 7823
55. T. Oka Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling Biochem. J. 432 2010 461 472
56. K. Duning KIBRA modulates directional migration of podocytes J. Am. Soc. Nephrol. 19 2008 1891 1903
57. K. Duning Polycystin-2 activity is controlled by transcriptional coactivator with PDZ binding motif and PALS1-associated tight junction protein J. Biol. Chem. 285 2010 33584 33588
58. E. Hwang Structural insight into dimeric interaction of the SARAH domains from Mst1 and RASSF family proteins in the apoptosis pathway Proc. Natl. Acad. Sci. U.S.A. 104 2007 9236 9241
59. H. Scheel, and K. Hofmann A novel interaction motif, SARAH, connects three classes of tumor suppressor Curr. Biol. 13 2003 R899 R900
60. M. Overholtzer Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon Proc. Natl. Acad. Sci. U.S.A. 103 2006 12405 12410
61. N. Zhang The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals Dev. Cell 19 2010 27 38
62. S. Benhamouche Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver Genes Dev. 24 2010 1718 1730
63. L. Lu Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver Proc. Natl. Acad. Sci. U.S.A. 107 2010 1437 1442
64. K.P. Lee The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis Proc. Natl. Acad. Sci. U.S.A. 107 2010 8248 8253
65. D.H. Gutmann Functional analysis of neurofibromatosis 2 (NF2) missense mutations Hum. Mol. Genet. 10 2001 1519 1529
66. R. Fossdal A novel TEAD1 mutation is the causative allele in Sveinsson's chorioretinal atrophy (helicoid peripapillary chorioretinal degeneration) Hum. Mol. Genet. 13 2004 975 981
67. L. Chen Structural basis of YAP recognition by TEAD4 in the hippo pathway Genes Dev. 24 2010 290 300
68. Z. Li Structural insights into the YAP and TEAD complex Genes Dev. 24 2010 235 240
69. X. Zhang The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene Oncogene 30 2011 2810 2822
70. M. Song Nuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancer Anticancer Res. 32 2012 3827 3834
71. A.A. Steinhardt Expression of Yes-associated protein in common solid tumors Hum. Pathol. 39 2008 1582 1589
72. V.K. Hill Frequent epigenetic inactivation of KIBRA, an upstream member of the Salvador/Warts/Hippo (SWH) tumor suppressor network, is associated with specific genetic event in B-cell acute lymphocytic leukemia Epigenetics 6 2011 326 332
73. M.Z. Xu Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma Cancer 115 2009 4576 4585
74. Y. Liu-Chittenden Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP Genes Dev. 26 2012 1300 1305
75. A.J. Houben, and W.H. Moolenaar Autotaxin and LPA receptor signaling in cancer Cancer Metastasis Rev. 30 2011 557 565
76. Y. Xu Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers JAMA 280 1998 719 723
77. M. Murph, and G.B. Mills Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression Expert Rev. Mol. Med. 9 2007 1 18
78. G.D. Prestwich Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer Biochim. Biophys. Acta 1781 2008 588 594
79. J.K. Fleming Biochemical and structural characterization of lysophosphatidic acid binding by a humanized monoclonal antibody J. Mol. Biol. 408 2011 462 476
80. J.M. Wojciak The crystal structure of sphingosine-1-phosphate in complex with a Fab fragment reveals metal bridging of an antibody and its antigen Proc. Natl. Acad. Sci. U.S.A. 106 2009 17717 17722
81. S. Ponnusamy Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis EMBO Mol. Med. 4 2012 761 775
82. S. Liu Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases Cancer Cell 15 2009 539 550
83. O. Cuvillier Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting Curr. Mol. Pharmacol. 3 2010 53 65
84. M.G. Kelly Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers Int. J. Gynecol. Cancer 21 2011 633 639
85. G. Jiang α-Substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA ChemMedChem 2 2007 679 690
86. R. Savai Targeting cancer with phosphodiesterase inhibitors Expert Opin. Investig. Drugs 19 2010 117 131
87. J.A. D'Orazio Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning Nature 443 2006 340 344
88. Z. Li, and J. Wang A forskolin derivative, FSK88, induces apoptosis in human gastric cancer BGC823 cells through caspase activation involving regulation of Bcl-2 family gene expression, dissipation of mitochondrial membrane potential and cytochrome c release Cell Biol. Int. 30 2006 940 946
89. B. Sun Coleusin factor exerts cytotoxic activity by inducing G0/G1 cell cycle arrest and apoptosis in human gastric cancer BGC-823 cells Cancer Lett. 301 2011 95 105
90. P. Goldhoff Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression Clin. Cancer Res. 14 2008 7717 7725
91. D.G. McEwan Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase Cancer Res. 67 2007 5248 5257
92. H.R. Bourne Hydrolysis of GTP by the α-chain of Gs and other GTP binding proteins Proteins 6 1989 222 230
93. S.W. Cole, and A.K. Sood Molecular pathways: β-adrenergic signaling in cancer Clin. Cancer Res. 18 2012 1201 1206
94. S.W. Chan WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ Oncogene 30 2011 600 610
95. C.Y. Liu PP1 cooperates with ASPP2 to dephosphorylate and activate TAZ J. Biol. Chem. 286 2011 5558 5566
96. E. Aragon A Smad action turnover switch operated by WW domain readers of a phosphoserine code Genes Dev. 25 2011 1275 1288
97. B. Zhao The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version Genes Dev. 24 2010 862 874
98. F. Kanai TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins EMBO J. 19 2000 6778 6791
99. J. Zhao 14-3-3 proteins as potential therapeutic targets Semin. Cell Dev. Biol. 22 2011 705 712
100. H. Hermeking The 14-3-3 cancer connection Nat. Rev. Cancer 3 2003 931 943
101. B. Schumacher Structure of a 14-3-3σ-YAP phosphopeptide complex at 1.15 A resolution Acta Crystallogr. Sect. F: Struct. Biol. Cryst. Commun. 66 2010 978 984
102. M. Cordenonsi The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells Cell 147 2011 759 772
103. P. Wang PP1A-mediated dephosphorylation positively regulates YAP2 activity PLoS ONE 6 2011 e24288
104. M.R. Swingle Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and (β12-β13)- chimeras (PP1/PP2A and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors J. Pharmacol. Exp. Ther. 331 2009 45 53
105. A. Hergovich, and B.A. Hemmings Hippo signalling in the G2/M cell cycle phase: lessons learned from the yeast MEN and SIN pathways Semin. Cell Dev. Biol. 23 2012 794 802
106. C.W. Lin MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1 Nat. Commun. 4 2013 1877
107. I. Lian The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation Genes Dev. 24 2010 1106 1118
108. E.R. Barry, and F.D. Camargo The Hippo superhighway: signaling crossroads converging on the Hippo/Yap pathway in stem cells and development Curr. Opin. Cell Biol. 25 2013 247 253